ABL Bio Inc.

298380· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩55,900-3.45%

2026-09-18

Financials

Valuation Metrics

ABL Bio Inc.'s Market Cap is ₩3.1T. At end of 2025 it was ₩11.2T. Ranked #149 of 2,421 in KR market (top 6%), #20 of 1,640 on KOSDAQ (top 1%), #11 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 5%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	3.13T KRW	KR#149/2,421 Sec#11/231
Revenue	34.28B KRW	KR#1,981/2,421 Sec#136/231
Net Income	-79.17B KRW	KR—/2,421 Sec—/231
Total Assets	273.72B KRW	KR#1,091/2,421 Sec#75/231
Net Assets	173.94B KRW	KR#1,037/2,421 Sec#72/231
Employees	104	KR#1,613/2,421 Sec#126/231
Value
P/B	17.99x	KR#2,399/2,421 Sec#222/231
P/S	91.29x	KR#2,388/2,421 Sec#207/231
FCF Yield	-1.32%	KR—/2,421 Sec—/231
Profitability
ROE	-45.51%	KR#2,264/2,421 Sec#193/231
ROA	-28.92%	KR#2,312/2,421 Sec#200/231
Op. Margin	-251.20%	KR#2,342/2,421 Sec#188/231
Revenue Growth	-63.89%	KR#2,313/2,421 Sec#209/231
Financial Health
Debt Ratio	57.37%	KR#1,064/2,421 Sec#124/231
Total Debt	55.00B KRW	KR#973/2,421 Sec#65/231
FCF	-41.38B KRW	KR#2,050/2,421 Sec#202/231
Cash	164.98B KRW	KR#316/2,421 Sec#13/231
Current Ratio	1.72x	KR#1,023/2,421 Sec#114/231
Performance
1Y Return	-44.27%	KR#1,933/2,421 Sec#165/231
1M Return	-29.86%	KR#2,354/2,421 Sec#222/231
From 52W High	-78.29%	KR#2,326/2,421 Sec#212/231
1Y MDD	-77.23%	KR#2,247/2,421 Sec#200/231
Trading
Volume	383,102 shares	KR#294/2,421 Sec#17/231
Trading Value	21.62B KRW	KR#154/2,421 Sec#9/231
Foreign Own.	13.48%	KR#359/2,421 Sec#24/231
Per Share
EPS	-1,414 KRW	KR—/2,421 Sec—/231
BPS	3,107 KRW	KR#1,840/2,421 Sec#137/231

Company Info

CEO 이상훈

Employees 104

Founded 2016

HQ 서울 강남구, KR

Website www.ablbio.com

동사는 2016년 설립돼 2018년 코스닥에 상장한 바이오의약품 연구개발 전문기업임. 이중항체 기술 플랫폼 'Grabody™'로 면역관문 조절, 신규 타깃 발굴, 퇴행성뇌질환 치료제, 항체-약물 접합체 등 항체치료제를 연구개발하고 있음. 경쟁력 있는 플랫폼과 다양한 파이프라인 확보, 기술이전을 통한 외형 확대와 엄격한 의사결정 체계를 적용하여 높은 가치 창출을 추구하고 있음. 에이비엘바이오는 2016년에 설립되었으며 서울 강남구에 본사를 두고 있습니다.